Ankylosing spondylitis primarily affects the joints and ligaments of the spine, but may also have an impact on other joints. Patients experience pain and stiffness that limit mobility in the back and other affected joints. Symptoms can come and go, last for long periods of time and be severe. Anti-tumor necrosis factor (anti-TNF) drugs are…
Search results for: cancer

Rheumatologists on the Move
Maura Daly Iversen Named Catherine Worthingham Fellow by APTA Maura Daly Iversen, PT, DPT, SD, MPH, FNAP, FAPTA, associate editor of The Rheumatologist, was recently named a Catherine Worthingham Fellow—the highest honor among the American Physical Therapy Association (APTA) membership categories. According to the award announcement, Worthingham “motivated others to make an impact within the…

Plaquenil: From Malaria Treatment to Managing Lupus, RA
In 1984, I wrote my first prescription for the antimalarial drug, hydroxychloroquine (Plaquenil), for a 28-year-old woman with SLE. She was considerably overweight, with inflammatory arthritis and a photosensitive rash, and I worried that oral corticosteroids would tip her over into diabetes. I presented the case to my attending, Steven Malawista, MD, at the Yale…
2014 ACR/ARHP Annual Meeting: Super Proteins Eyed in Therapies for Rheumatic Diseases
Immunoglobulin superfamily of proteins, CTLA-4 and PD-1, may generate treatments for RA, SLE
2014 ACR/ARHP Annual Meeting: Regulatory T Cells
Rheumatology experts explore ways Treg cells contribute to autoimmune diseases, RA
The ACR Recommends Cautious Approach as Biosimilars Enter U.S. Market
With the U.S. FDA’s first approval of a biosimilar drug earlier this month, rheumatologists stress the need to ensure safety, efficacy of such drugs in treating rheumatic diseases
Certolizumab Pegol Drug Studies Find No New Safety Issues
Plus, updates on clazakizumab, hydrocodone bitartrate extended-release capsules and other rheumatology drug news, safety information
Skin Disease in Rheumatology Patients Should Prompt Collaboration with Dermatologists
Patients with conditions that don’t resolve with topical steroids are signal for referral
UNC’s Thurston Arthritis Research Center in the Spotlight
Approachability, collaboration foster excellence in this basic science, clinical and epidemiological research program
2014 ACR/ARHP Annual Meeting: Lupus Nephritis
Multi-targeted, aggressive drug therapies needed for complete response, remission of this lupus complication
- « Previous Page
- 1
- …
- 64
- 65
- 66
- 67
- 68
- …
- 85
- Next Page »